Paul SK, Montvida O, Best JH, et al. - Researchers conducted this retrospective pharmacoepidemiological outcomes study to investigate possible links between treatment with biological disease-modifying antirheumatic drugs (bDMARDs), including T-cell-based and interleukin-6 inhibition (IL-6i)-based therapies, and the risk for type 2 diabetes mellitus (T2DM) in rheumatoid arthritis (RA) patients. Five treatment groups were chosen from a United States Electronic Medical Records database of 283,756 RA patients (mean follow-up, 5 years): never received bDMARD (No bDMARD, n = 125,337), tumour necrosis factor inhibitors (TNFi, n = 34,873), IL-6i (n = 1,884), T-cell inhibitors (n = 5,935) and IL-6i+T cell inhibitor abatacept ( n= 1,213). According to results, treatment with IL-6i, with or without T-cell inhibitors, was linked to a lower risk of T2DM compared with TNFi or No bDMARDs; the T-cell inhibitor abatacept had a less pronounced association.